Liver carcinoma
|
0.700 |
AlteredExpression
|
disease |
BEFREE |
RT‑PCR demonstrated that the mRNA expression levels of IGF2R were downregulated in HCC compared with in TST samples (P=0.004), which was associated with a worse recurrence‑free survival of patients with HCC (P=0.002) and a lower occurrence of cirrhosis (P=0.05).
|
30720132 |
2019 |
Liver carcinoma
|
0.700 |
AlteredExpression
|
disease |
BEFREE |
DX-2647, a recombinant human antibody, potently neutralizes the action of insulin-like growth factor-II (IGF-II), a ligand for three cell-surface receptors (IGF-IR, insulin receptor A and B isoforms, and the cation-independent mannose-6-phosphate receptor) which is overexpressed in primary human HCC.
|
29933129 |
2018 |
Liver carcinoma
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
The combination of IGF-2+3580 AA homozygosity and IGF-2R 1619 GG homozygosity presented a significant protective effect against HCC (OR=0.16,95% CI=0.08-0.34, P=0.005).
|
24656929 |
2014 |
Liver carcinoma
|
0.700 |
GeneticVariation
|
disease |
LHGDN |
These results show M6P/IGF2R LOH predicts poor clinical outcomes in surgically resected primary HCC patients.
|
18322954 |
2008 |
Liver carcinoma
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
These results show M6P/IGF2R LOH predicts poor clinical outcomes in surgically resected primary HCC patients.
|
18322954 |
2008 |
Liver carcinoma
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
Moreover, these M6P/IGF2R 3'UTR mutations and the TP53 mutations detected previously were mutually exclusive in most of the tumors, suggesting two independent pathways to HCC development, with the TP53 pathway being more favored with increasing radiation dose than the M6P/IGF2R pathway.
|
17149973 |
2006 |
Liver carcinoma
|
0.700 |
Biomarker
|
disease |
CTD_human |
Total RNA was extracted from individual HCCs for assessment of mutations within exons 27, 28, 31, 33, and 34, and aberrant transcript of the M6p/Igf2r gene by reverse transcription (RT)-polymerase chain reaction (PCR)-single strand conformation polymorphism (SSCP) and RT-PCR analyses, respectively.
|
15057872 |
2004 |
Liver carcinoma
|
0.700 |
Biomarker
|
disease |
LHGDN |
Effects of insulin-like growth factors-IR and -IIR antisense gene transfection on the biological behaviors of SMMC-7721 human hepatoma cells.
|
12603530 |
2003 |
Liver carcinoma
|
0.700 |
AlteredExpression
|
disease |
BEFREE |
Compared with corresponding non-tumor tissues, expression of the M6P/IGF2R mRNA was decreased in 13/19 (68%) HBV-positive HCC tissues, suggesting that M6P/IGF2R may be involved in HBV-associated hepatocarcinogenesis by the regulation of its expression level.
|
12736721 |
2003 |
Liver carcinoma
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
In conclusion, M6P/IGF2R is mutated in HCCs from throughout Japan with a frequency similar to that in the United States.
|
11981765 |
2002 |
Liver carcinoma
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
The latter is homologous to the human M6P/IGF2r coding sequence which is mutated in human hepatocellular carcinoma.
|
10411141 |
1999 |
Liver carcinoma
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
Recently, it was reported in the United States that loss of heterozygosity (LOH) and mutations in exons 27, 28, and 31 of the M6P/IGF2R gene are frequent in hepatocellular carcinomas (HCCs) and adenomas.
|
10347113 |
1999 |
Liver carcinoma
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
M6P/IGF2R allele loss was also found in cirrhotic tissue of clonal origin adjacent to these dysplastic lesions and HCCs, demonstrating that M6P/IGF2R inactivation occurs early in liver carcinogenesis.
|
9294214 |
1997 |
Liver carcinoma
|
0.700 |
Biomarker
|
disease |
BEFREE |
The frequent allelic loss and homozygous deletion of the M6P/ IGF2r gene suggest that the M6P/IGF2r gene functions as a tumor suppressor gene in the development of HCC.
|
9570384 |
1997 |
Liver carcinoma
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
M6P/IGF2R gene is mutated in human hepatocellular carcinomas with loss of heterozygosity.
|
7493029 |
1995 |
Liver carcinoma
|
0.700 |
AlteredExpression
|
disease |
BEFREE |
Transforming growth factor-beta receptors and mannose 6-phosphate/insulin-like growth factor-II receptor expression in human hepatocellular carcinoma.
|
7639583 |
1995 |
Liver carcinoma
|
0.700 |
Biomarker
|
disease |
HPO |
|
|
|
Liver carcinoma
|
0.700 |
CausalMutation
|
disease |
CGI |
|
|
|
Liver carcinoma
|
0.700 |
CausalMutation
|
disease |
CLINVAR |
|
|
|